Konvuleks - Instructions For Use, Reviews, Price, Drops, Syrup

Table of contents:

Konvuleks - Instructions For Use, Reviews, Price, Drops, Syrup
Konvuleks - Instructions For Use, Reviews, Price, Drops, Syrup

Video: Konvuleks - Instructions For Use, Reviews, Price, Drops, Syrup

Video: Konvuleks - Instructions For Use, Reviews, Price, Drops, Syrup
Video: Neopeptine Drop & Syrup : Benefits, Ingredients,Dose In Hindi 2023, December


Konvuleks: instructions for use and reviews

  1. 1. Release form and composition
  2. 2. Pharmacological properties
  3. 3. Indications for use
  4. 4. Contraindications
  5. 5. Method of application and dosage
  6. 6. Side effects
  7. 7. Overdose
  8. 8. Special instructions
  9. 9. Application during pregnancy and lactation
  10. 10. Use in childhood
  11. 11. In case of impaired renal function
  12. 12. For violations of liver function
  13. 13. Use in the elderly
  14. 14. Drug interactions
  15. 15. Analogs
  16. 16. Terms and conditions of storage
  17. 17. Terms of dispensing from pharmacies
  18. 18. Reviews
  19. 19. Price in pharmacies

Latin name: Convulex

ATX code: N03AG01

Active ingredient: valproic acid (acidum valproicum)

Producer: G. L. Farma, GmbH (GLPharma, GmbH) (Austria), Catalent Germany Eberbach, GmbH (Germany)

Description and photo updated: 28.08.

Prices in pharmacies: from 110 rubles.


Enteric capsules
Enteric capsules

Konvulex is an anticonvulsant drug.

Release form and composition

  • Drops for oral administration: transparent, colorless or slightly yellowish solution (100 ml in vials with a dispenser, 1 vial in a cardboard box);
  • Syrup for children: colorless or slightly yellowish liquid with a fruity aroma (100 ml in dark glass vials, complete with a measuring syringe, 1 set in a cardboard box);
  • Sustained-release film-coated tablets: oval, biconvex, white, almost white or white at the break, with a vanilla aroma, on one side there is a break line separating the engraving (depending on dosage) "CC | 3" - 300 mg, "CC | 5" - 500 mg (50 pcs., 100 pcs. In polypropylene bottles or dark glass bottles, 1 bottle in a cardboard box);
  • Enteric capsules: soft gelatinous, pink, enteric coated; gray ink marking indicates dose - “150”, “300” or “500”; the contents of the capsules are liquid with a characteristic faint odor, colorless or slightly yellowish (150 and 500 mg - 10 pcs. in blisters, 10 blisters in a cardboard box; 300 mg - 20 pcs. in blisters, 5 blisters in a cardboard box);
  • Solution for intravenous (IV) administration: clear liquid, colorless or almost colorless (5 ml each in colorless glass ampoules, 5 ampoules in plastic trays, 1 tray in a cardboard box).

Each pack also contains instructions for the use of Konvuleks.

Composition of 1 ml drops for oral administration:

  • Active ingredient: sodium valproate - 300 mg;
  • Auxiliary components: sodium saccharinate, orange flavor, hydrochloric acid 37%, sodium hydroxide, purified water.

Composition of 1 ml syrup for children:

  • Active ingredient: sodium valproate - 50 mg;
  • Auxiliary components: liquid maltitol (lycasin 80/55), sodium cyclamate, sodium saccharinate, sodium chloride, methyl parahydroxybenzoate, propyl parahydroxybenzoate, peach flavor, raspberry flavor, purified water.

Composition of 1 prolonged-release film-coated tablet:

  • Active ingredient: sodium valproate - 300 or 500 mg;
  • Auxiliary components: citric acid, eudragit RS30D, ethylcellulose, talc, magnesium stearate, colloidal silicon dioxide;
  • Film casing: eudragit RS30D, eudragit RL30D type A, triethyl citrate, titanium dioxide, sodium carmellose, talc, vanillin.

Composition of 1 enteric capsule:

  • Active ingredient: valproic acid - 150, 300 or 500 mg;
  • Auxiliary components of the capsule body: glycerol 85%, gelatin, Karion 83, titanium dioxide, hydrochloric acid 25%, red iron oxide (E172);
  • Enteric coating: polysorbate-80, sodium lauryl sulfate, triethyl citrate, glyceryl monostearate 45-55 type II, macrogol 6000;
  • Capsule labeling ink: shellac 47.5%, black iron oxide dye, titanium dioxide, butanol, propylene glycol, isopropanol, denatured ethanol (methylated alcohol), water.

Composition of 1 ml solution for intravenous administration:

  • Active ingredient: sodium valproate / valproic acid - 100 mg / 86.78 mg (1 ampoule - 500 mg / 433.9 mg);
  • Auxiliary components: disodium hydrogen phosphate dodecahydrate, sodium hydroxide, distilled water.

Pharmacological properties


The active component of Konvulex is valproic acid, which is part of the drug in the form of sodium valproate. It belongs to the group of fatty acid derivatives, has antiepileptic efficacy, has a sedative and central muscle relaxant effect.

The mechanism of action of the substance is mainly due to the inhibition of the enzyme GABA-transferase, as a result of which the content of GABA (gamma-aminobutyric acid) in the central nervous system increases. GABA helps to reduce the excitability and seizure readiness of the motor areas of the cerebral cortex. In addition, an important pharmacological effect of valproic acid is its effect on ligand-dependent ion channels in the chemical synapses of the nervous system (GABA A-receptors), inhibiting the transmission of nervous excitement (activation of GABAergic transmission), as well as the effect on voltage-gated sodium channels. In another hypothesis, the effect of a substance on the sites of postsynaptic receptors with an imitation or an increase in the inhibitory effect of GABA is considered. A possible direct effect on membrane function is associated with the transformation of conductivity for potassium ions.

Valproic acid preparations improve the mood and mental state of patients, have an antiarrhythmic effect.


  • Absorption: valproic acid is absorbed in the gastrointestinal tract almost completely, the bioavailability of oral forms of the drug is 100%. Simultaneous intake with food has no effect on the rate of absorption. Plasma index C max (maximum concentration) is achieved 1-3 hours after administration. Equilibrium concentration when taking Konvuleks inside (enteric capsules, prolonged-release tablets, oral drops, syrup for children) is achieved on days 2-4 of treatment and depends on the frequency of taking the drug. With the introduction of Konvulex IV, the equilibrium concentration of valproic acid is achieved in a few minutes and can be maintained using a slow infusion of the solution;
  • Distribution: the indicator of the plasma therapeutic concentration of the drug varies from 50 to 150 mg / l. The substance binds to plasma proteins at a concentration of up to 50 mg / l at a level of 90–95%, at a concentration of 50–100 mg / l - 80–85%. Uremia, hypoproteinemia and cirrhosis of the liver reduce binding to plasma proteins. The concentration in the cerebrospinal fluid depends on the value of the fraction of valproic acid not bound to plasma proteins, and is about 10% of the serum level;
  • Metabolism: biotransformation of valproic acid occurs by glucuronidation and oxidation in the liver;
  • Excretion: mainly unchanged valproic acid (1-3% of the dose) and its metabolites are excreted by the kidneys and only in small quantities - with feces, as well as with exhaled air. T 1/2 value (half-life): with monotherapy in healthy volunteers is 8-20 hours, in complex therapy with drugs that induce microsomal liver enzymes and are involved in the metabolism of valproic acid, it can be from 6 to 8 hours, with hepatic impairment function, in elderly patients and children under 1.5 years of age, the T 1/2 value can be significantly higher.

Valproic acid crosses the placental and blood-brain barriers, during lactation it is excreted in breast milk at a level of 1-10% of the concentration in the mother's blood.

Indications for use

Syrup for children

  • Epileptic seizures (including partial, generalized and seizures due to organic brain diseases);
  • Epilepsy of any origin;
  • Epilepsy-related behavioral disorders;
  • Febrile seizures
  • Bipolar disorder (bipolar disorder) that does not respond to therapy with lithium or other anticonvulsants.

Enteric capsules, extended-release tablets, drops for oral administration, solution for intravenous administration

  • Epilepsy of various origins (cryptogenic, idiopathic, symptomatic);
  • Partial epileptic seizures in children and adults (with or without secondary generalization);
  • Generalized epileptic seizures in children and adults (tonic, clonic, tonic-clonic, myoclonic, atonic, absences);
  • Specific syndromes (Lennox-Gastaut, Vesta);
  • Behavioral disorders due to epilepsy;
  • Febrile seizures, baby tics;
  • Therapy and prevention of bipolar disorder; for prolonged-release tablets - therapy and prevention of bipolar disorder that cannot be treated with lithium or other anticonvulsants.



  • Severe thrombocytopenia;
  • Hemorrhagic diathesis;
  • Pancreatic dysfunction;
  • Liver failure;
  • Porphyria;
  • Chronic and acute hepatitis;
  • Combination with St. John's wort, lamotrigine, mefloquine;
  • Disorders of urea metabolism, including data in the family history;
  • Body weight in children less than 20 kg (extended-release tablets);
  • Body weight in children less than 7.5 kg (oral drops);
  • Breastfeeding (lactation) period;
  • Age up to 3 years (extended-release tablets and capsules);
  • Hypersensitivity to valproic acid and its salts or other components of Konvulex.

Relative (take with caution due to the increased likelihood of side effects):

  • Anamnestic data on diseases of the pancreas and liver, including data in the family history;
  • Inhibition of bone marrow hematopoiesis (thrombocytopenia, leukopenia, anemia);
  • Renal failure;
  • Congenital fermentopathies (enzymopathies);
  • Organic brain diseases;
  • Hypoproteinemia;
  • Pregnancy, especially in the first trimester;
  • Mental retardation in children;
  • Body weight in children from 7.5 kg or more (drops for oral administration);
  • Therapy in children with several antiepileptic drugs (solution);
  • Multiple concomitant diseases and severe seizures in children and adolescents (solution);
  • Age up to 3 years (solution).

Konvulex, instructions for use: method and dosage

Enteric capsules, extended-release tablets, oral drops, syrup for children (oral forms of the drug)

Capsules and tablets are taken orally, during meals or immediately after meals, without chewing, with a little water. Dosage regimen: capsules - 2-3 times a day; tablets - 1-2 times a day.

Konvulex drops are taken orally with a small amount of water, regardless of the meal. Dosing regimen - 2-3 times a day.

The syrup is taken orally with a small amount of liquid, regardless of the meal. The daily dose of Konvuleks is divided into 2-3 doses.

The initial dose for adults is 600 mg / day, then it is gradually increased every 3 days by 150-250 mg until the seizures disappear (a clinical effect is achieved).

With monotherapy, the initial dose of Konvuleks is 5-15 mg / kg / day, then it is gradually increased by 5-10 mg / kg per week.

The recommended daily dose is 20-25 mg / kg (about 1000-2000 mg). If necessary, the dose can be increased to a maximum of 30 mg / kg (2500 mg).

The maximum daily dose is 30 mg / kg / day, but for patients with accelerated metabolism of valproic acid, it can be increased to 60 mg / kg / day (subject to control of the concentration of valproic acid in the blood plasma).

For combination therapy, the recommended dose of Konvuleks is 10-30 mg / kg / day, with a further increase of 5-10 mg / kg per week.

For children weighing 7.5-25 kg for monotherapy, an average daily dose of 15-45 mg / kg is recommended, the maximum is 50 mg / kg. As part of complex therapy - 30-100 mg / kg per day.

For children weighing more than 25 kg, an initial daily dose of Konvulex is recommended 5-15 mg / kg (about 300 mg), with an increase in the future by 5-10 mg / kg per week until the seizures disappear (achieving a clinical effect), while the dose, as a rule, it is 20-30 mg / kg (1000-1500 mg).

It should be borne in mind that in children weighing up to 20 kg, it is not recommended to use the drug in the form of prolonged-release tablets, they should be replaced with other forms of Konvulex.

Recommended average daily doses of Konvuleks in capsules, depending on the patient's weight:

  • 7.5-14 kg - 150-450 mg / day: 1-3 capsules of 150 mg;
  • 14-21 kg - 300-600 mg / day: 2-4 capsules of 150 mg each or 1-2 - 300 mg each;
  • 21-32 kg - 600-900 mg / day: 4-6 capsules of 150 mg each or 2-3 - 300 mg each;
  • 32-50 kg - 900-1500 mg / day: 3-5 capsules of 300 mg each or 2-3 - 500 mg each;
  • 50-90 kg - 1500-2500 mg / day: 3-5 capsules of 500 mg.

Recommended average daily doses of Konvulex drops depending on the patient's weight:

  • 7.5-14 kg - 150-450 mg (15-45 drops);
  • 14-21 kg - 300-600 mg (30-60 drops);
  • 21-32 kg - 600-900 mg (60-90 drops);
  • 32-50 kg - 900-1500 mg (90-150 drops);
  • 50-90 kg - 1500-2500 mg (150-250 drops).

Average daily doses of Konvulex syrup for children, depending on the weight of the child:

  • 7.5-14 kg - 150-450 mg (3-9 ml);
  • 14-21 kg - 300-600 mg (6-12 ml);
  • 21-32 kg - 600-900 mg (12-18 ml).

Solution for intravenous administration

Konvulex is administered by infusion or intravenously slowly.

Recommended daily intake:

  • Intravenous - 5-10 mg / kg;
  • Infusion - 0.5-1 mg / kg.

Doses of the drug do not change when switching from oral forms to intravenous administration. After the last ingestion, IV administration is recommended after 12 hours. In the future, IV administration is replaced by the intake of Konvuleks inside, as soon as the patient's condition allows, an interval of 12 hours from the last IV administration to the first oral administration should also be maintained.

The recommended dosing regimen for the rapid achievement and maintenance of a high concentration of valproic acid in plasma: inject Konvulex intravenously at a dose of 15 mg / kg for 5 minutes, after 0.5 h, start the infusion at a rate of 1 mg / kg / h (while maintaining a constant monitoring the concentration of the drug in plasma until a value of about 75 μg / ml is reached).

Average daily doses of the solution, depending on the age category:

  • Adults, including elderly patients - 20 mg / kg;
  • Adolescents - 25 mg / kg;
  • Children - 30 mg / kg.

The maximum daily dose is 2500 mg.

For dilution, it is allowed to use 5% glucose solution, isotonic sodium chloride solution, Ringer's solution. The prepared solution for infusion should be used within 1 day, and the unused volume should be destroyed. In the case of simultaneous intravenous use of other drugs, Konvulex must be administered through a separate infusion system.

It is advisable for elderly patients to more carefully select the dose of the drug, taking into account the possible use of reduced doses.

In case of renal failure, it may be necessary to reduce the dose of Konvuleks, selecting it according to the results of observations of the clinical condition, since data on the concentration of valproic acid in the plasma may be insufficiently informative.

Side effects

If the recommended dosage regimen is observed, Konvulex is generally well tolerated by patients.

Adverse reactions from organs and systems, mainly arising when the level of Konvuleks in plasma exceeds 100 mg / l, or in the case of using the drug as part of complex therapy:

  • Digestive system: gastralgia, nausea, vomiting, anorexia or bulimia, hepatitis, diarrhea; rarely - constipation (constipation), pancreatitis;
  • Central nervous system (CNS): diplopia, tremor, flashing "flies" before the eyes, nystagmus; rarely - changes in mood, behavior or mental state (feeling tired, depression, hallucinations, hyperactivity, aggressiveness, psychosis, restlessness, unusual agitation, irritability), dizziness, drowsiness, ataxia, headache, stupor, dysarthria, impaired consciousness, coma;
  • Hematopoietic system: leukopenia, thrombocytopenia, anemia, decreased platelet aggregation, fibrinogen content and blood clotting, accompanied by petechial hemorrhages, prolonged bleeding time, bruising, bleeding, hematomas;
  • Metabolism: increase or decrease in body weight;
  • Endocrine system: secondary amenorrhea, galactorrhea, dysmenorrhea, breast enlargement;
  • Laboratory indicators: hypercreatininemia, hyperbilirubinemia, hyperammonemia, a slight dose-dependent increase in the activity of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH);
  • Allergic responses: urticaria, skin rash, angioedema, Stevens-Johnson syndrome, photosensitivity;
  • Other: swelling, hair loss (usually, after the cancellation of Konvulex, hair is restored).


Symptoms of an overdose of valproic acid are: dizziness, nausea / vomiting, diarrhea, impaired respiratory function, hyporeflexia, muscle hypotension, miosis, coma.

In case of an overdose of oral forms of Konvuleks, it is recommended to wash the stomach followed by the intake of absorbents (for example, activated carbon), but no later than 10–12 hours after taking high doses of sodium valproate inside. The second stage of therapy is carrying out hemodialysis procedures and forced diuresis while maintaining the vital systems of the body (respiratory and cardiovascular).

Treatment of overdose with intravenous administration of high doses of Konvuleks begins immediately from the second stage.

special instructions

Due to the available information about severe (including fatal) episodes of pancreatitis and liver failure, the following facts should be considered when using valproic acid:

  • High-risk group - children from birth to 3 years of age with severe epilepsy (often due to brain damage) and congenital degenerative or metabolic pathologies;
  • Functional disorders of the liver mainly develop in the first 0.5 years of treatment (usually from 2 to 12 weeks), more often when using Konvulex as part of complex therapy;
  • Cases of pancreatitis are observed regardless of the age of the patient and the duration of the course of therapy, but the risk of developing the disease decreases with increasing age of the patient;
  • The likelihood of death increases in the presence of liver failure;
  • Diagnosis at an early (pre-icteric) stage is based primarily on the results of clinical observations and consists in identifying early signs such as anorexia, asthenia, drowsiness, extreme fatigue, sometimes against a background of vomiting and abdominal pain; in addition, with unchanged antiepileptic therapy, a relapse of epileptic seizures may occur.

In any of these cases, you should immediately consult a doctor for a clinical examination and analysis of liver function.

During therapy, especially in the first six months, liver function should be periodically monitored: ALT and AST activity, bilirubin concentration, fibrinogen, prothrombin, coagulation factors, and amylase activity (every 3 months, especially during Konvulex therapy in combination with other antiepileptic drugs) and a picture of peripheral blood, including platelets.

Patients receiving other antiepileptic substances / drugs, transfer to valproic acid should be carried out gradually, reaching a clinically effective dose within 2 weeks, after which a gradual withdrawal of previously taken drugs is permissible. If Konvulex is the first antiepileptic drug taken by the patient, then the clinically effective dose should be reached within 1 week.

The likelihood of developing adverse reactions from the liver is increased in children, as well as during combined anticonvulsant treatment.

Along with Konvulex, you should not take drinks containing ethanol.

Before the operation, it is necessary to do a general blood test, including determining the number of platelets, coagulogram indicators, and bleeding time.

If the symptom complex "acute abdomen" occurs during treatment, the activity of amylase in the blood should be determined before surgery in order to exclude acute pancreatitis.

During therapy, it is necessary to take into account the likelihood of distortion of the results of urine tests in diabetes mellitus (due to an increase in the content of ketone bodies) and indicators of thyroid function.

If any serious acute adverse reactions develop, you should immediately discuss with your doctor the advisability of stopping or continuing the course.

To reduce the risk of developing dyspeptic disorders, it is recommended to take antispasmodics and enveloping medicines.

The abrupt cessation of the use of Konvulex can provoke an increase in the frequency of epileptic seizures.

Women of reproductive age should use reliable contraceptives during therapy, since it has been established in experimental studies that Konvulex has a teratogenic effect.

Influence on the ability to drive vehicles and complex mechanisms

Care should be taken when driving vehicles and engaging in potentially hazardous activities that require quick psychomotor reactions and increased concentration.

Application during pregnancy and lactation

During therapy, it is necessary to use reliable contraception. In the course of experimental studies on animals, the teratogenic effectiveness of valproic acid was confirmed. According to reliable data, the intake of valproic acid in humans mainly causes such defects in the intrauterine development of the fetus as myelomeningocele (spinal hernia), spina bifida (1-2%). Episodes of limb malformations (in particular their shortening), facial dysmorphia, and malformations of the cardiovascular system were recorded. The risk of developmental defects is higher with combination treatment than with sodium valproate as monotherapy.

Based on the available data, the use of Konvulex during pregnancy is permissible only if there is a clinically significant excess of the intended benefit to the mother over the risk to the fetus. It is not recommended to start treatment in the first trimester of pregnancy. If the treatment with valproic acid started before conception is effective at the onset of pregnancy, it should not be interrupted. In this case, it is recommended to switch to monotherapy using the drug in the minimum effective daily dose, which should be divided into two doses. In order to minimize the risk of neural tube malformations in the fetus, folic acid (vitamin B 9) preparations can be used in combination with antiepileptic therapy in a daily dose of 5 mg.

The hemorrhagic syndrome that valproic acid can cause in newborns is likely associated with hypofibrinogenemia. Cases of the development of afibrinogenemia were observed, leading to death, possibly associated with a decrease in the activity of a number of blood coagulation factors.

In newborns whose mothers have taken Konvulex therapy, the number of platelets, plasma fibrinogen levels and blood coagulation factors are necessarily determined.

Valproic acid during lactation is excreted in breast milk in concentrations of 1-10%, and therefore it is recommended to stop breastfeeding while taking Konvuleks.

Pediatric use

Contraindications for taking Konvulex in pediatrics, depending on the form of release of the drug:

  • Sustained-release film-coated tablets: children under 3 years of age, weight of a child less than 20 kg;
  • Syrup for children: no contraindications;
  • Enteric capsules: children under 3 years of age;
  • Drops for oral administration: the child weighs less than 7.5 kg, the drops are prescribed with caution to children weighing more than 7.5 kg;
  • Solution for intravenous administration: it is prescribed with caution to children under the age of 3 years, if necessary, complex therapy with several antiepileptic drugs, as well as to children and adolescents with multiple concomitant diseases and in the case of severe seizures.

Konvulex is prescribed with caution in any form of release to children with mental retardation.

With impaired renal function

Konvulex is contraindicated for use in patients with metabolic disorders of the urea cycle (including in a family history). With caution, therapy is carried out with renal failure.

For violations of liver function

Konvulex is contraindicated for use in patients with hepatic insufficiency, in acute and chronic hepatitis. With care, therapy is carried out if there is a history of liver disease.

Use in the elderly

Pharmacokinetic characteristics of valproic acid in elderly patients may have their own characteristics, but since their clinical significance is limited, it is recommended to determine the dose according to the therapeutic efficacy of the drug. Since binding with serum albumin decreases with age, the proportion of unbound valproic acid in the plasma increases. Therefore, it is advisable to more carefully select the dose of Konvuleks for elderly patients, taking into account the possibility of its reduction.

Drug interactions


  • Mefloquine: enhances the metabolism of valproic acid, reduces its concentration in plasma; at the same time, the anticonvulsant effect of mefloquine decreases (such a combination leads to an increase in the risk of epileptic seizures);
  • St. John's wort (ordinary): there is a possibility of a decrease in the concentration of valproic acid in the blood plasma.

Require special care:

  • Zidovudine: an increase in plasma concentration, as a result of which its toxicity increases;
  • Carbamazepine: the concentration of its active metabolite in plasma increases to symptoms of overdose; the concentration of valproic acid decreases and its hepatic metabolism increases (medical supervision is recommended, including the concentration of drugs in plasma, it may be necessary to adjust the doses);
  • Carbapenems, monobactams (panipenem, meropenem, aztreonam, imipenem): reduce the plasma concentration of valproic acid, possibly reducing the anticonvulsant effect of Konvulex;
  • Clonazepam: in isolated cases, an increase in the severity of the absence status is possible;
  • Neuroleptics, antidepressants, monoamine oxidase (MAO) inhibitors, benzodiazepines: the effectiveness of Konvuleks decreases, while the effect of these psychotropic drugs and benzodiazepines is potentiated;
  • Primidone, phenobarbital: their concentration in plasma increases to symptoms of overdose (mainly in children), hepatic metabolism of valproic acid increases, its concentration in plasma decreases (the first 2 weeks of complex therapy require determination of the concentration in the blood of the level of anticonvulsants and clinical observation; in case of signs sedation should immediately reduce the dose of primidone or phenobarbital);
  • Topiramate: the likelihood of developing encephalopathy and hyperammonemia increases;
  • Felbamate: increases the concentration of valproic acid in plasma by 35-50%, there is a danger of overdose (clinical observation and determination of the level of concentration of valproic acid in the blood is required, a change in its dose when combined with felbamate, and when it is canceled);
  • Phenytoin: a change in its concentration in plasma is likely, as well as a decrease in the concentration of valproic acid and an increase in its hepatic metabolism (it is recommended to determine the level of concentration of antiepileptic substances in the blood, clinical observation and, if necessary, change doses);
  • Erythromycin, cimetidine: hepatic metabolism of valproic acid is suppressed, its concentration in plasma increases;
  • Ethosuximide: due to changes in metabolism, its concentration in the blood serum can both increase and decrease (it is necessary to determine the level of concentration of antiepileptic substances in the blood, clinical observation and, if necessary, dose adjustment).


  • Acetylsalicylic acid: enhances the effects of valproic acid as a result of its displacement from the bond with plasma proteins; the action of acetylsalicylic acid is mutually enhanced;
  • Myelotoxic drugs: the likelihood of inhibition of bone marrow hematopoiesis increases;
  • Indirect anticoagulants: their effect is enhanced, it is required to carefully monitor the value of the prothrombin index when combined with vitamin K-dependent anticoagulants;
  • Nimodipine: increased hypotensive effect, since valproic acid, suppressing metabolism, increases its concentration in plasma;
  • Hepatotoxic agents, ethanol: increased risk of liver damage.


  • Oral contraceptives: Konvulex, without causing induction of microsomal liver enzymes, does not reduce the effectiveness of hormonal oral contraceptives;
  • Lamotrigine: increases the risk of severe allergic skin reactions such as toxic epidermal necrolysis (this drug combination is not recommended, but close laboratory and clinical monitoring is required if necessary).


Konvuleks analogs are: Depakin, Depakin Chrono, Valparin, Valparin XP, Keppra, Enkorat, Enkorat Chrono, Konvulsofin.

Terms and conditions of storage

Keep out of the reach of children:

  • Tablets, solution, syrup, drops - at temperatures up to 25 ° C;
  • Capsules - up to 30 ° C.

The shelf life is 5 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Konvuleks

In most reviews about Konvuleks, patients and parents of children in need of antiepileptic and anticonvulsant therapy note the high efficacy of the drug and its rapid action. At the same time, it is emphasized that the drug must be taken only as directed by a doctor, in the prescribed dosage form, with strict adherence to the recommended dosage regimen.

Konvulex relieves seizures and convulsive activity well, soothes headaches, and can also reduce aggressiveness, irritability and depressive mood.

The disadvantages are high prices, a large number of contraindications and side effects. Cases of excess weight gain, hair loss, vomiting are described.

Price for Konvulex in pharmacies

Estimated price of Konvuleks:

  • Sustained-release film-coated tablets, 50 pcs. in the package: dosage 300 mg - 310–348 rubles, 500 mg - 499–540 rubles;
  • Enteric capsules: dosage 300 mg, 100 pcs. in the package - 329 rubles, dosage 500 mg, 100 pcs. in the package - 380 rubles;
  • Syrup for children 50 mg / ml: 100 ml in a dark glass bottle, complete with a measuring syringe - 135–249 rubles;
  • Solution for intravenous administration 100 mg / ml: ampoule 5 ml, 5 pcs. in the package - 1253-1484 rubles;
  • Drops for oral administration 300 mg / ml: 100 ml in a dark glass bottle with a dosing device - 191-235 rubles.

Konvulex: prices in online pharmacies

Drug name



Konvulex 50 mg / ml syrup for children 100 ml 1 pc.

110 RUB


Konvulex 300 mg / ml drops for oral administration 100 ml 1 pc.

RUB 138


Konvulex 300 mg film-coated tablets of prolonged action 50 pcs.

274 r


Konvulex tablets p.p. prolonged action 300mg 50 pcs.

327 r


Konvulex tablets p.p. prolonged action 500mg 50 pcs.

456 r


Konvulex 500 mg tablets of prolonged action film-coated 50 pcs.

456 r


Konvulex 100 mg / ml solution for intravenous administration 5 ml 5 pcs.

1181 RUB


Konvulex solution for intravenous injection 100mg / ml 5ml 5 pcs.

1431 RUB


See all offers from pharmacies
Anna Kozlova
Anna Kozlova

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!